Sugi Predict

Sugi Predict / Targets / HSD17B13

HSD17B13

17-beta-hydroxysteroid dehydrogenase 13 · Q7Z5P4 · HSD17B13 on Sugi Atlas →

10,412 patent compounds predicted against HSD17B13, 5,914 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5822973 SCHEMBL5822973 0.56 13/20
SCHEMBL2456869 SCHEMBL2456869 0.41 10/20
SCHEMBL6537576 SCHEMBL6537576 0.41 8/20
SCHEMBL3537778 SCHEMBL3537778 0.50 6/20
SCHEMBL3710899 SCHEMBL3710899 0.53 5/20
SCHEMBL5209564 SCHEMBL5209564 0.53 5/20
SCHEMBL1640330 SCHEMBL1640330 0.43 5/20
SCHEMBL2734502 SCHEMBL2734502 0.38 5/20
SCHEMBL3244183 SCHEMBL3244183 0.54 4/20
SCHEMBL1528807 SCHEMBL1528807 0.53 4/20
SCHEMBL1114431 SCHEMBL1114431 0.52 4/20
SCHEMBL1529125 SCHEMBL1529125 0.52 4/20
SCHEMBL1114354 SCHEMBL1114354 0.52 4/20
SCHEMBL5250819 SCHEMBL5250819 0.51 4/20
SCHEMBL1114355 SCHEMBL1114355 0.50 4/20
SCHEMBL1528976 SCHEMBL1528976 0.50 4/20
SCHEMBL2212039 SCHEMBL2212039 0.47 4/20
SCHEMBL4538500 SCHEMBL4538500 0.46 4/20
SCHEMBL3790038 SCHEMBL3790038 0.46 4/20
SCHEMBL4927547 SCHEMBL4927547 0.45 4/20

Clinical trials — most relevant to HSD17B13 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment PHASE4RECRUITING
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study PHASE3UNKNOWN
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS) PHASE3COMPLETED
Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy PHASE3COMPLETED
Androgen Reduction in Congenital Adrenal Hyperplasia PHASE2WITHDRAWN
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia PHASE1/PHASE2COMPLETED
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer PHASE2RECRUITING
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma PHASE2UNKNOWN
Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia PHASE2COMPLETED
AMG 386 and Abiraterone for Advanced Prostate Cancer PHASE2COMPLETED
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency PHASE1COMPLETED
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency nanUNKNOWN
Linear Growth of Children With Congenital Adrenal Hyperplasia nanUNKNOWN
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers nanUNKNOWN
Final Height in Patients With CAH nanUNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas nanUNKNOWN
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency nanCOMPLETED
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome nanCOMPLETED
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN
Impact of 11-oxygenated Androgens on Metabolic Dysfunction of Women With Polycystic Ovary Syndrome nanUNKNOWN
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH nanCOMPLETED
Cortisol Regulation in Polycystic Ovary Syndrome (PCOS) nanCOMPLETED
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension nanUNKNOWN
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological Changes nanNOT_YET_RECRUITING
Novel Biomarker for Development of T2D nanCOMPLETED
Adrenal Function in GHD Children nanCOMPLETED
Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS) nanCOMPLETED
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a HSD17B13 binder may also engage these)

ProteinNameSimilarity
Q4JK73 — 1.000 Q4JK73 →
Q5M875 — 1.000 Q5M875 →
Q5NVG2 — 1.000 Q5NVG2 →
HSD17B11 Estradiol 17-beta-dehydrogenase 11 1.000 landscape →
Q8N3Y7 — 1.000 Q8N3Y7 →
Q8VCR2 — 1.000 Q8VCR2 →
A5PJJ7 — 0.998 A5PJJ7 →
Q05A13 — 0.998 Q05A13 →
Q7T2D1 — 0.998 Q7T2D1 →
Q9EQ06 — 0.998 Q9EQ06 →
Q6AYS8 — 0.997 Q6AYS8 →
Q9STY7 — 0.997 Q9STY7 →
P0DKC6 — 0.995 P0DKC6 →
P0DKC5 — 0.995 P0DKC5 →
Q80ZF7 — 0.995 Q80ZF7 →
Q8HZT6 — 0.994 Q8HZT6 →
Q8IZV5 — 0.994 Q8IZV5 →
A1L1W4 — 0.994 A1L1W4 →
Q8VCH7 — 0.994 Q8VCH7 →
Q5XGF7 — 0.993 Q5XGF7 →
Q6DCT3 — 0.992 Q6DCT3 →
Q7TQA3 — 0.991 Q7TQA3 →
Q17704 — 0.991 Q17704 →
O17795 — 0.991 O17795 →
Q6NRV4 — 0.991 Q6NRV4 →
P70385 — 0.991 P70385 →
Q6QA32 — 0.991 Q6QA32 →
Q5ZJG8 — 0.990 Q5ZJG8 →
A5PJF6 — 0.990 A5PJF6 →
Q9STY8 — 0.990 Q9STY8 →